Abbott (ABT) Price on Solana

Abbott Laboratories agreed on September 15, 2026 to pay approximately $385 million to settle False Claims Act allegations tied to a contamination investigation at its Sturgis, Michigan infant formula plant. The settlement, reached with the U.S. Department of Justice and Medicaid-participating states, includes over $384 million plus interest paid to the government, with three whistleblower employees receiving $69 million as their share. Abbott admitted no fault or liability under the terms.

The Sturgis facility was closed in February 2022 after FDA inspectors found Cronobacter sakazakii bacteria in five environmental samples and documented facility problems including roof leaks and faulty equipment. Four infants contracted the rare bacterium and two deaths were potentially linked to the infections. The plant closure deepened the national infant formula shortage that had already been strained by COVID-19 supply disruptions. A whistleblower lawsuit was filed in October 2022, the DOJ partially intervened in 2025, and a formal complaint followed in November 2025 before the settlement was reached.

Abbott Laboratories (ABT) has lagged the healthcare sector by a wide margin in 2026, falling 11.8% year-to-date while the State Street Health Care Select Sector SPDR ETF (XLV) is up 10.2% — a 22-point gap. Over the past 52 weeks the divergence is steeper still, with ABT down 15.8% against XLV's roughly 25% gain, and the stock sitting nearly 20% below its 52-week high of $137.49. Rival Johnson & Johnson has outpaced Abbott even more sharply, rising 28.6% YTD and 51.7% over the past year. Analysts attribute the underperformance to weaker demand in Abbott's Nutrition and Diagnostics segments, post-COVID normalization of COVID-related diagnostic volumes, lingering concerns around the infant-formula business, and integration challenges stemming from the Exact Sciences acquisition.

Despite the drag, a consensus of 29 analysts rates ABT a "Strong Buy" with a mean price target of $121.33, representing roughly 10% upside from current levels. The stock has also traded above its 50-day moving average since late June, signaling some technical stabilization. A notable reversal appeared in the most recent three-month window, with ABT gaining 29.2% versus XLV's 14.1%, suggesting the market may be beginning to price in a catch-up as the Nutrition and Diagnostics headwinds ease.

The FDA cleared Abbott's Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System on August 28, 2026, making it the first wearable in the U.S. approved to continuously track both blood sugar and ketone levels simultaneously in a single device. Cleared via the De Novo regulatory pathway for new low-to-moderate-risk devices, the system is approved for patients aged two and older with diabetes and provides up to ten days of continuous wear, alerting users when ketone levels rise — replacing the traditional single-point urine or blood tests that have long been the standard for diabetic ketoacidosis monitoring.

The approval rested on six clinical studies involving over 600 participants, with trial data demonstrating the sensor accurately tracks clinically significant ketone variations. Abbott plans to integrate the Libre Duo with automated insulin delivery systems from Beta Bionics and Sequel Med Tech by end of 2026, and with Insulet, Tandem Diabetes Care, and MiniMed platforms in 2027. William Blair analysts flagged the pediatric segment as the most competitive near-term opportunity, particularly once AID pump integrations come online next year.

Abbott Laboratories has agreed to pay $670 million to settle a high-profile lawsuit and related claims alleging that its cow's milk-based premature infant formula, Similac, causes necrotizing enterocolitis (NEC) — a severe intestinal disease in which tissue lining the intestine becomes inflamed and dies. The settlement resolves the case that produced a $495 million appellate judgment in 2026, including a Missouri jury award of $95 million in compensatory and $400 million in punitive damages on behalf of a premature infant who required removal of 75% of her intestine after developing NEC. Abbott admitted no liability and stated it "believes these agreements are in its best long-term interest."

Despite the settlement, Abbott's litigation exposure remains substantial: roughly 1,700 lawsuits covering approximately 12,700 infants are still pending nationwide. The company's CEO had previously floated the possibility of discontinuing the formula product entirely given the litigation volume, a prospect that alarmed physicians who rely on it for premature infants without access to breast milk. Government agencies including the FDA, CDC, and NIH stated in 2024 that there is no conclusive evidence that preterm infant formula causes NEC, though research shows associations between cow's milk formulas and elevated NEC rates. The $670 million payout adds meaningful near-term financial pressure while the broader docket remains unresolved.

Abbott and Alphabet announced a multi-year collaboration on August 11, 2026, integrating real-time data from Abbott's Lingo continuous glucose monitor into Google's Health app. Lingo is a non-prescription CGM biowearable that tracks metabolic data—blood glucose, nutrition response, sleep, and recovery—without a doctor's prescription, positioning it at the consumer wellness end of Abbott's diabetes care portfolio. Under the partnership, Lingo data feeds into Google's AI Health Coach, which then surfaces personalized guidance tied to a user's actual biometric readings rather than generic population averages.

The deal extends Abbott's digital health ambitions beyond the clinical market it dominates with FreeStyle Libre, tapping Google's consumer reach and AI infrastructure to drive Lingo adoption at scale. Abbott's Diabetes Care segment reported 10.5% revenue growth in Q2 2026, contributing to company-wide quarterly sales of $12.59 billion—up 13% year-over-year. Pairing Lingo's real-time metabolic data with a widely used health platform could accelerate the consumer CGM category while giving Abbott a direct channel into preventive health management, where recurring device usage and subscription-adjacent engagement models represent meaningful long-term revenue opportunities.

Abbott Laboratories completed a share repurchase program totaling approximately $1.35 billion, with 14,015,097 shares acquired in total and 11,599,094 of those purchased between April and June 2026. A Simply Wall St valuation analysis places ABT's fair value at $119.13 per share against a closing price of $107.81, implying the stock could be roughly 10% undervalued. The model weighs revenue growth, margin expansion, and product-mix improvement, with emerging market expansion across India, China, Latin America, and the Middle East — alongside biosimilar launches — underpinning expectations of continued double-digit top-line growth.

Despite a strong 90-day gain of nearly 28%, Abbott shares remain down about 13% year-to-date, weighed in part by the April acquisition of Exact Sciences in a $23 billion deal that initially diluted near-term guidance. Analysts note ongoing pricing pressure in diagnostics and glucose monitoring, along with tariff and foreign exchange headwinds, as key risks to the valuation case. For shareholders, the completed buyback signals management's view that ABT is attractively priced, while the Exact Sciences integration and emerging-market pipeline position the company for longer-term earnings growth.

A federal judge dismissed a securities fraud lawsuit against Abbott Laboratories on July 24, 2026, stemming from the company's February 2022 recall of powdered infant formula products — Similac, Alimentum, and EleCare — manufactured at its Sturgis, Michigan facility. U.S. District Judge Steven Seeger of the Northern District of Illinois ruled that shareholders, led by two European asset managers, failed to demonstrate that Abbott intended to deceive investors or artificially inflate its stock price, writing that "Mismanaging a plant that makes infant formula is bad. But it's not securities fraud."

Shareholders had alleged Abbott delayed disclosing bacterial contamination to regulators, concealed poor plant conditions, and made false statements about regulatory compliance. Abbott held more than 40% of the U.S. infant formula market before the recall, which contributed to a national formula shortage. The court found the claims insufficient and indicated that amending the complaint would likely be futile.

Abbott disclosed on July 17, 2026 that it is investigating two separate cyber incidents involving unauthorized access to internal systems. The first affected internal systems within its cancer diagnostics business, while the second involved the LabCentral portal, a third-party-hosted, externally facing platform used by its core laboratory diagnostics unit. Abbott said it has engaged outside cybersecurity experts and law enforcement and that no other businesses, sites, or systems were impacted by either incident.

The company stated that operations were not affected and that it does not expect any material impact on its business or financial results. On the LabCentral breach, Abbott noted that the portal contained only publicly available technical documents such as manuals, troubleshooting guides, and product specifications, with no known exposure of sensitive customer or business information. The disclosures come amid a broader wave of cyberattacks targeting healthcare companies across the industry.

Abbott shares rallied after the company reported second-quarter sales of $12.6 billion, up 13% year-over-year, and adjusted earnings per share of $1.31 — beating analyst expectations of $1.28. Diagnostics was the standout segment, with sales surging 42.3% to $3.1 billion, driven in large part by Abbott's $21 billion acquisition of Exact Sciences in March, which added the Cologuard colorectal cancer screening test to its portfolio. Medical devices grew 9% to $5.9 billion, with continuous glucose monitor sales rising 11%.

Management raised its full-year adjusted EPS outlook to a range of $5.45–$5.60, up from a prior forecast of $5.38–$5.58, and guided full-year comparable sales growth of 6.5%–7.5% for 2026. The stronger-than-expected results also reinforce Abbott's position as a dividend compounder — the company has raised its dividend for 54 consecutive years.

Baird initiated coverage on Abbott Laboratories (ABT) with an Outperform rating and a $121 price target, citing the company's diversified portfolio as a foundation for steady top-line and earnings growth over the next several years. The firm's thesis centers on Abbott's medical devices segment, which it views as positioned for above-peer performance, supported by new product launches and expanding indication opportunities expected to provide a clearer upside path into fiscal 2027-2028.

Abbott's business spans medical devices, diagnostics, nutrition, and established pharmaceuticals. Baird pointed to healthy procedure volumes and favorable capital expenditure trends across the MedTech and diagnostics sectors as near-term tailwinds supporting the outlook.